Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 10:2019:6856327.
doi: 10.1155/2019/6856327. eCollection 2019.

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease

Chao-Chao Yu  1 , Tao Jiang  1 , Ao-Fei Yang  2   3 , Yan-Jun Du  1 , Miao Wu  2   3 , Li-Hong Kong  1
Affiliations
Review

Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease

Chao-Chao Yu et al. Neural Plast. .

Abstract

Tau hyperphosphorylation is a typical pathological change in Alzheimer's disease (AD) and is involved in the early onset and progression of AD. Epigenetic modification refers to heritable alterations in gene expression that are not caused by direct changes in the DNA sequence of the gene. Epigenetic modifications, such as noncoding RNA regulation, DNA methylation, and histone modification, can directly or indirectly affect the regulation of tau phosphorylation, thereby participating in AD development and progression. This review summarizes the current research progress on the mechanisms of epigenetic modification associated with tau phosphorylation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Isoforms of tau protein. The six isoforms of tau are by alternative splicing of exons 2, 3, and 10.
Figure 2
Figure 2
Epigenetic modulation on tau phosphorylation and possible impacts on synapses and neurons. Dysregulated epigenetic modification on genes associated with the tau phosphorylation process could lead to NFT aggregation which can then cause neuroinflammation, axonal transport dysfunction, and mitochondrial and synaptic plasticity injuries.
See this image and copyright information in PMC

References

    1. Nativio R., Donahue G., Berson A., et al. Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease. Nature Neuroscience. 2018;21(4):497–505. doi: 10.1038/s41593-018-0101-9. - DOI - PMC - PubMed
    1. Prince M., Wimo A., Guerchet M., Ali G. C., Wu Y. T., Prina M. World Alzheimer report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. https://www.alz.co.uk/research/world-report-2015.
    1. Hane F. T., Lee B. Y., Leonenko Z. Recent progress in Alzheimer’s disease research, part 1: pathology. Journal of Alzheimer’s Disease. 2017;57(1):1–28. doi: 10.3233/JAD-160882. - DOI - PubMed
    1. Brunet A., Berger S. L. Epigenetics of aging and aging-related disease. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2014;69(Supplement 1):S17–S20. doi: 10.1093/gerona/glu042. - DOI - PMC - PubMed
    1. Alzheimer’s Association. 2016 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2016;12(4):459–509. doi: 10.1016/j.jalz.2016.03.001. - DOI - PubMed

Publication types